Ameliorant for hepatitis C therapeutic effect and application thereof
US6455051B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2000 |
| Grant date | Sep 24, 2002 |
| Priority date | — |
| Expiry date | Apr 12, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/217
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an ameliorant for enhancing the therapeutic effect of IFN-&agr; on hepatitis C; a therapeutic composition for the treatment of hepatitis C which comprises IFN-&agr; and IFN-&ggr; as active ingredients and further contains a pharmaceutically acceptable carrier; a kit for the treatment of hepatitis C which comprises an IFN-&agr; preparation and an IFN-&ggr; preparation; and a therapeutic method for the treatment of hepatitis C which comprises administering IFN-&agr; and IFN-&ggr; to a subject at the same time or administering IFN-&ggr; before the administration of IFN-&agr;. The present invention is capable of making the patient continuously HCV-RNA negative and is extremely useful in the treatment of chronic hepatitis C which is intractable with, IFN-&agr; and conventionally difficult to remedy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.